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Abstract: Two sensitive, precise and cost-effective UV-spectrophotometric methods are described for the
determination of terbinafine hydrochloride (TFH) in bulk drug and tablets. The methods are based on the
measurement of absorbance of TFH in 0.1M HCl at 222 nm in method A and in 0.1M acetic acid at 282 nm in
method B. As per the International Conference on harmonization ICH guidelines, the methods were validated
for linearity, accuracy, precision, limits of detection (LOD), limit of quantification (LOQ), robustness and
ruggedness. Beer’s law is obeyed over the concentration ranges of 0.2-4.0 and 2.0-50.0 μg mL-1 TFH in method
A and method B, respectively, and the corresponding molar absorptivity values are 8.7 x 104 and 7.9 x 103 L
mol-1 cm-1. The proposed methods were applied successfully to the determination of TFH in tablets with good
accuracy, precision and without any detectable interference from tablets excipients. The validity and reliability
of the proposed methods were further assed by the recovery studies via a standard addition method. In addition,
forced degradation of TFH was conducted in accordance with the ICH guidelines. Acidic, basic and water
hydrolysis, thermal stress, peroxide and photolytic degradation were used to assess the stability indicating
power of the methods. Slight degradation was observed during base degradation in method A and substantial
degradation was observed during oxidative degradation in both methods. No degradation was observed under
other stress conditions.
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Introduction.
Terbinafine hydrochloride (TFH), chemically known as (E)-N-(6,6-dimethyl- 2 - hepten - 4 - ynyl) -N-
methyl - 1 – naphthalene methanamine hydrochloride [29], is a potent antifungal agent of the allylamine class
with broad spectrum activity against yeasts, dimorphic fungi, molds, and dermatophytes [23,22,2,4].
Various techniques have been used for the determination of TFH in body fluids and pharmaceuticals.
The drug is official in European Pharmacopoeia [14], British Pharmacopoeia [6] and the United States
Pharmacopoeia [30]. European Pharmacopoeia and British Pharmacopoeia describe acid-base titration in hydro-
alcoholic medium, the end point being located potentiometrically [14,6]. United States Pharmacopoeia describes
high performance liquid chromatographic method for the estimation of TFH [30] . High performance liquid
chromatography (HPLC) has been applied for the determination of TFH and metabolites in human plasma [10],
TFH and metabolites in human plasma, milk and urine [26], metabolites in human plasma [32] and the drug in
tissues [31]. An improved high throughput liquid chromatographic/tandem mass spectrophotometric method for
TFH in plasma [11] and ultra performance liquid chromatographic method for the drug and its metabolites in
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human plasma and urine [5] are the other chromatographic methods reported for body fluids. In addition
microbiological assay  for the drug are also found in the literature [18, 21].
Several HPLC procedures [28,15,17,25,1,7,24] employing different columns and mobile phases have
been reported for its assay in dosage forms when present alone [28,15,17,25,1,7] or in combination with
bezafibrate [24]. High performance thin layer chromatography (HPTLC) has recently been applied for the assay
of drug in tablets [27] and for the simultaneous determination of TFH and triamcinolone acetamide in
compound tablets [13]. Non-aqueous titrimetry [8] visible spectrophotometry [12,16,9] and voltammetry  [3] are
the other analytical techniques available for the assay of TFH in its dosage forms.
UV-spectrophotometry is one of the simplest techniques routinely used in pharmaceutical quality
control laboratories because of its sensitivity, speed, fair selectivity, low cost and ease of performance.
However, the literature on TFH is poor with regard to UV-spectrophotometric methods. In a method reported by
Cardoso and Schapoval [8], the absorbance of methanolic extract of tablets and creams was measured at 224
nm. Simultaneous determination of TFH and triamcilone acetamide  by derivative spectrophotometry has been
reported by EL-Saharty et.al [13].
Stability indicating assay are increasingly being applied to many pharmaceutically important
compounds [19]. But, none of the methods available for TFH [28,15,17,25,1,7,24,27,13,8] including the UV-
spectrophotometric methods [13,8] is stability indicating. The objective of the present study was to develop
simple, sensitive and rapid uv-spectrophotometric methods which are stability indicating. The methods are




Shimadzu Pharmaspec 1700 UV/Visible spectrophotometer was used for absorbance measurements.
Materials
Pharmaceutical grade terbinafine hydrochloride (TFH) was received from Dr. Reddy’s laboratories
limited, Hyderabad, India, as gift sample and used as received. Zimig-250 (from Glaxo Smith Kline
Pharmaceuticals Limited, India) and Terbiforce-250 (from Lifestar Pharma PVT. Ltd.) tablets were purchased
from commercial sources in the local market. All reagents and chemicals used were of analytical reagent grade
and distilled water was used throughout the study. Solutions of hydrochloric acid, 0.1M and 2M (Merck,
Mumbai, India, Sp. gr. 1.18), acetic acid, 0.1M (Merck, Mumbai, India; Sp. gr.1.048-1.050 ), sodium hydroxide,
2M (Merck, Mumbai, India) and 5% hydrogen peroxide (Merck, Mumbai, India 30% w/v) were prepared in
double distilled water and used for degradation studies.
Standard drug solution
Standard drug solutions of 10 μg mL-1 TFH prepared in 0.1M HCl for  assay in method A and 100 μg
mL-1 of TFH prepared in 0.1M acetic acid for assay in method B .
Procedures
Method A (Using 0.1M HCl)
Aliquots (0.00, 0.2, 0.5, 1.0, …4.0 mL ) of TFH standard solution (10 μg mL-1) were accurately
transferred into a series of 10 mL calibrated flasks and the volume was made up to the mark with 0.1M HCl.
The absorbance of each solution was measured at 222 nm against 0.1M HCl blank.
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Method B (Using 0.1M acetic acid)
Aliquots (0.00, 0.2, 0.5, 1.0, ….5.0 mL) of TFH standard solution (100 μg mL-1) were accurately
transferred into a series of 10 mL volumetric flasks and the volume was made up to the mark with 0.1M acetic
acid. The absorbance of each solution was measured at 282 nm against 0.1M acetic acid blank.
In both the cases, calibration curves were plotted and the concentration of the unknown was read from
the calibration graph are computed from regression equation derived using Beer’s law data.
Procedure for tablets
Twenty tablets were weighed accurately and ground into a fine power. An accurately weighed amount
of the tablet powder equivalent to 10 mg of TFH was transferred into two 100 mL calibrated flasks. Sixty mL of
0.1 M HCl was added to one and 0.1 M acetic acid to other flask and the content was shaken thoroughly for 15-
20 min to extract the drug into the liquid phase; the volume was finally diluted to the mark with the respective
solvent, mixed well and filtered using a whatman No. 42 filter paper. The filtrate (100 μg mL-1) was subjected to
analysis by following procedures described above after appropriate dilution in method A.
Procedure for placebo blank analysis
A placebo blank of the composition: talc (50 mg), starch (50 mg), acacia (50mg), methyl cellulose (20
mg), sodium citrate (20 mg), magnesium stearate (20 mg) and sodium alginate (10 mg) was made and its
solution was prepared by taking 20 mg as described under ‘Procedure for tablets’, and then analysed using the
procedure described earlier.
Procedure for the determination of TFH in synthetic mixture
To 20 mg of the placebo blank of the composition described above, 10 mg of TFH was added and
homogenized, transferred to a 100 mL calibrated flask and the solution was prepared as described under
“Procedure for tablets”, and then subjected to analysis by the procedure described above. This analysis was
performed to study the interference by excipients such as talc, starch, acacia, methyl cellulose, sodium citrate,
magnesium stearate and sodium alginate.
Preparation of acid, base and water hydrolysis induced-degradation of sample
For acid, alkaline and water hydrolysis degradation studies to 2.0 mL of 10 μg mL-1 stock solution of
TFH, 2.5 mL of 2M HCl or 2M NaOH or water were added separately in method A, and to 2.0 mL of 100 μg
mL-1 stock solution of TFH, 2.5 mL of 2M HCl or 2M NaOH or water were added separately in three 10 mL
calibrated flasks in method B. The flasks were kept on a water bath set at 80oC for 3.0 hrs, then cooled to room
temperature. Then the solutions were neutralized with equal volume of 2M NaOH or 2M HCl. The content of
each flask was made up to the mark with 0.1 M HCl in method A and with 0.1M acetic acid in method B. The
absorption spectrum was run from 200-400 nm.
Preparation of hydrogen peroxide induced-degradation of sample
To 2.0 mL of TFH standard solution (10 μg mL-1 for method A and 100 μg mL-1 for method B) 2.5 mL of
5% hydrogen peroxide was added in 10 mL calibrated flasks. The flasks were kept on a water bath set at 800C
for 3.0 hrs. The flasks were cooled room temperature, made up to the mark with 0.1M HCl, 0.1M NaOH in
method A and method B respectively. The absorption spectrum of each was run from 200-400 nm.
Preparation of dry heat degradation and photo-degradation samples.
The powdered drug was stored in the oven at 1050C for 48 hrs to study dry heat degradation, and
exposed to 200 watt hr. m-2, UV-radiation and 1.2 million lux hr. of visible radiation for study of photo
degradation. After that solutions containing 2 μg mL-1 TFH in 0.1 M HCl and 20 μg mL-1 TFH in 0.1 M acetic
acid were prepared for method A and method B, respectively. The absorption spectra were run from 200-400
nm.
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Results And Discussions.
In the present work, two UV-spectrophotometric methods for the determination of TFH in bulk drug
and in tablets have been described. In method A 0.1 M HCl was used as the solvent and the absorbance was
measured at 222 nm (Figure 1) where in method B, 0.1M acetic acid was used as a solvent with the
measurement being made at 282 nm (Figure 2).
Figure 1 Figure 2
Figure 1: (Absorption spectra of 2 µg mL-1 TFH in 0.1M HCl, Method A))
Figure 2: (Absorption spectra of 20 µg mL-1 TFH in 0.1M Acetic acid, Method B)
Stability Property
The absorption spectra of the TFH solutions treated with acid, base, hydrogen peroxide, dry heat and
UV radiation were run in the range of (200-400 nm). The degradation study was based on the comparison of the
UV spectra of “stressed TFH samples” with that of the “standard TFH solution”. The absorption spectrum of
TFH solution treated with 2M hydrochloric acid (Figure 3 and 4) showed the same spectrum of the standard
solution (Figure 1 and 2) which shows that TFH does not undergo degradation under acidic conditions in both
methods.
     Figure 3 Figure 4
Figure 3: UV-spectra of TFH after subjected to acidic degradation (Method A).
Figure 4: UV-spectra of TFH after subjected to acidic degradation (Method B).
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Also the spectra of TFH solution treated with 2M sodium hydroxide indicate slight degradation in
method A (Figure 5)  and no significant degradation in method B (Figure 6) when compared to standard (Figure
1 and 2).
Figure 5 Figure 6
Figure 5: UV-spectra of TFH after subjected to base degradation (Method A).
Figure 6: UV-spectra of TFH after subjected to base degradation (Method B).
 From Figure 7, 8, 9, 10, 11, and 12, it is clear that TFH is quite stable under water, dry heat and UV-
Visible exposure stress conditions.
Figure 7 Figure 8
Figure 7: UV-spectra of TFH after subjected to water degradation (Method A).
Figure 8: UV-spectra of TFH after subjected to water degradation (Method B).
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       Figure 9 Figure 10
Figure 9: UV-spectra of TFH after subjected to thermal degradation (Method A).
Figure 10: UV-spectra of TFH after subjected to thermal degradation (Method B).
       Figure 11 Figure 12
Figure 11: UV-spectra of TFH after subjected to photolytic degradation (Method A).
Figure 12: UV-spectra of TFH after subjected to photolytic degradation (Method B).
Contrary to the above discussions, the absorption spectrum of TFH solution subjected to oxidative stress
conditions showed that TFH undergoes significant degradation (Figure 13, 14) in both the methods.
Figure 13 Figure 14
Figure 13: UV-spectra of TFH after subjected to oxidative degradation (Method A).
Figure 14: UV-spectra of TFH after subjected to oxidative degradation (Method B).
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Method validation
The proposed methods were validated as per ICH guidelines [20] for linearity, sensitivity, precision,
accuracy robustness, ruggedness and selectivity.
Linearity, sensitivity, limits of detection and quantification
A linear correlation was found between absorbance at λmax and concentration of TFH in the ranges given
in Table I. The graphs are described by the regression equation : Y= a +bX (where Y-absorbance of 1-cm layer
of solution; a-intercept; b-slope and X-concentration in µg mL-1). Regression analysis of the Beer’s law data
using the method of least squares was made to evaluate the slope (b), intercept (a) and regression coefficient (r2)
for each system and the values are presented in Table I. The optical characteristics such as Beer’s law limits,
molar absorptivity and Sandell sensitivity values of the two methods are also given in Table I. The limits of
detection (LOD) and quantification (LOQ) calculated according to ICH guidelines [20] using the formule : LOD
= 3.3 S/b and LOQ = 10 S/b, (where S is the standard deviation of blank absorbance values, and b is the slope of
the calibration plot) are also presented in Table I. The high values of ε and low values of Sandell sensitivity and
LOD indicate the high sensitivity of the proposed methods.
Table I. Sensitivity and regression parameters
Parameter Method A Method B
λmax, nm 222 282
Linear range, μg mL-1 0.2 – 4.0 2.0 – 50.0
Molar absorptivity (ε), L mol-1 cm-1 8.72 X 104 7.97 X 103
Sandell sensitivity*, μg cm-2 0.0038 0.0411
Limit of detection (LOD), μg mL-1 0.003 0.09
Limit of quantification (LOQ), μg mL-1 0.01 0.27
Regression equation, Y**
Intercept (a) 0.0076 -0.0035
Slope (b) 0.2584 0.0247
Standard deviation of a (Sa) 0.003411 0.028083
Standard deviation of b (Sb) 0.001518 0.000925
Regression coefficient (r2) 0.9999 0.9997
* Limit of determination as the weight in μg per mL of solution, which corresponds to an absorbance of
A=0.001 measured in a cuvette of cross-sectional area 1 cm2 and l= 1cm. **Y=a+bX, Where Y is the
absorbance, X is concentration in μg mL-1, a is intercept, b is slope.
Accuracy and precision
Accuracy was evaluated as percentage relative error between the measured concentrations and the
concentrations taken for TFH (Bias %). Precision of the method was calculated in terms of intermediate
precision (intra-day and inter-day). Three different concentrations of TFH were analyzed in seven replicates
during the same day (intra-day precision) and for six consecutive days (inter-day precision). RSD (%) values of
the intra-day and inter-day studies showed that the precision was satisfactory. The results obtained are compiled
in Table II and show that the accuracy is good.
Robustness and ruggedness
Method robustness and ruggedness were demonstrated by determination of TFH at three different
conditions. Method robustness was tested by measuring the absorbance at different wave lengths where the
method ruggedness was performed by four different analysts, and also with three different cuvettes by a single
analyst. The intermediate precision, expressed as percent RSD, which is a measure of robustness and ruggedness
was within the acceptable limits as shown in the Table III.
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Table II. Evaluation of intra-day and inter day accuracy and precision
Intra-day accuracy and precision
(n=7)




μg mL-1 TFH found,μg mL-1 % RE %RSD
TFH found,
μg mL-1 % RE %RSD
1.5 1.50 0.30 0.14 1.50 0.20 0.14
2.5 2.49 0.43 0.25 2.49 0.53 0.30A
3.5 3.48 0.71 0.32 3.48 0.45 0.32
15 14.86 0.94 0.17 14.81 1.26 0.27
25 24.91 0.37 0.16 24.91 0.37 0.16B
35 34.86 0.40 0.27 34.77 0.64 0.30
%RE. Percent relative error, %RSD. Relative standard deviation.
Table III. Method robustness and ruggedness expressed as intermediate precision (%RSD)
Ruggedness





1.5 0.64 0.53 0.91
2.5 0.76 0.58 0.56A
3.5 0.85 0.71 0.60
15 0.76 0.76 0.98
25 0.88 0.81 0.78B
35 0.71 0.56 0.69
#Wavelengths used were 221, 222 and 223 in method A and 281,282 and 283 in method B.
Selectivity and interference
The proposed methods were tested for selectivity by placebo blank and synthetic mixture analyses. The
placebo blank solution was subjected to analysis according to the recommended procedures and found that there
was no interference from the inactive ingredients, indicating a high selectivity for determining TFH in its
tablets. A separate experiment was performed with the synthetic mixture. The analysis of synthetic mixture
solution yielded percent recoveries of 99.61+0.75 for method A and 99.56+0.85 for method B, indicating the
non-interference by inactive ingredients.
Application to tablets
In order to evaluate the analytical applicability of the proposed method to the quantification of TFH in
commercial tablets, results obtained by the proposed methods were compared to those of the reference method
[6] by applying Students’s t-test for accuracy and F-test for precision. The reference method which describes
acid-base titration in hydro-alcoholic medium and the end point being located potentiometrically. The results
showed that the Students’s t- and F-values at 95% confidence level did not exceed the tabulated values, which
confirmed that there is a good agreement between the results obtained by the proposed methods and the
reference method with respect to accuracy and precision (Table IV).
Recovery studies
The accuracy and validity of the proposed methods were further ascertained by performing recovery
studies. Pre-analysed tablet powder was spiked with pure TFH at three concentration levels (50, 100 and 150%
of that in tablet powder) and the total was found by the proposed methods. The added TFH recovery percentage
values ranged from 99.2-100.5% with standard deviation of 0.38-0.87 indicating that the recovery was good,
and that the co-formulated substance did not interfere in the determination (Table V).
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Table IV. Results of analysis of tablets by the proposed methods and statastical comparison of the results
with the reference method
Found* (Percent of label claim +SD)
Tablet brand name Nominal amount(mg/tablet) Reference
method Method A Method B
99.12+0.72 97.48+0.60
Zimig®* 250 98.6+1.13 t =0.87 t=1.97
F=2.46 F=3.55
99.62+0.67 100.30+0.62
TERBIFORCE# 250 98.8+1.20 t =1.34 t =2.47
F=3.21 F=3.75
* Mean value of 5 determinations.
Tabulated t-value at the 95% confidence level and for four degrees of freedom is 2.77. Tabulated F-value
at the 95% confidence level and for four degrees of freedom is 6.39.
Marketed by: *GlaxoSmithKline, #Lifestar Pharma pvt. Ltd.
Conclusion
Two simple UV-spectrophotometric methods for the determination of TFH in bulk drug and in
pharmaceutical dosage form were developed and validated as per ICH guidelines. The proposed methods rely on
the use of simple technique but provide sensitivity comparable to that achieved by sophisticated and expensive
technique like HPLC. Stress testing is an important aspect of the drug development process. The present
methods require simple and low cost instrumental setup and involve minimal manipulation producing relatively
more and accurate results. From this study it can be conclude that TFH quite stable to several stress conditions
such as acid, hydrolysis, dry heat treatment and photo oxidation conditions whereas it undergoes degradation
under base and oxidation conditions. Moreover, the proposed methods have the advantages of simplicity and
high sensitivity and are free from such experimental variables as heating or extraction step. The methods have
been demonstrated to be free from interference by common tablet excipients and additives, so they can be used
as alternative for rapid and routine determination of bulk sample and formulation.
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Table V. Results of recovery study via standard-addition method.































1.5 0.75 2.25 99.73+0.87 15 7.5 22.44 99.21+0.48
Zimig®* 1.5 1.5 2.99 99.51+0.78 15 15 29.91 99.38+0.64
1.5 2.25 3.74 99.47+0.81 15 22.5 37.52 100.09+0.38
1.5 0.75 2.25 99.44+0.50 15 7.5 22.50 100.04+0.48
TERBIFORCE# 1.5 1.5 3.00 100.19+0.78 15 15 30.03 100.23+0.74
1.5 2.25 3.73 99.23+0.41 15 22.5 37.62 100.53+0.76
*Mean value of three determinations.
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